Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Douglas Nguyen

Gastroenterology Mission Viejo, CA Medical Doctor

NPI 1184880114 CMS profile 454183

27799 Medical Center Rd Ste 310, Mission Viejo, CA 92691

Open in the dashboard

General payments

$2,036,599

2,510 records reported · program years 2019–2025

Research payments

$1,925

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$212,481 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Douglas Nguyen of Mission Viejo, CA is reported in the CMS Open Payments database as having received $2,036,599 across 2,510 general payments and $1,925 in research payments paid to them. Separately, studies naming them as principal investigator received $212,481 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $406,320 546
2024 General $486,934 667
2023 General $369,355 461
2022 General $306,227 357
2021 General $188,135 197
2020 General $119,797 105
2020 Research $1,925 1
2019 General $159,831 177

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Douglas Nguyen
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Douglas Nguyen were reported at $406,320. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Douglas Nguyen Gastroenterology median Middle half National median
2019 $159,831 $417 $126–$1,100 $163
2020 $119,797 $224 $74–$624 $114
2021 $188,135 $352 $106–$1,054 $132
2022 $306,227 $448 $129–$1,270 $149
2023 $369,355 $533 $150–$1,390 $160
2024 $486,934 $605 $160–$1,606 $164
2025 $406,320 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $777,747 881 payments
  2. Janssen Biotech, Inc. $339,617 394 payments
  3. E.R. Squibb & Sons, L.L.C. $267,591 189 payments
  4. Janssen Scientific Affairs, LLC $244,141 227 payments
  5. Lilly USA, LLC $221,255 254 payments
  6. Pfizer Inc. $87,423 100 payments
  7. Celltrion USA Inc. $44,888 47 payments
  8. Eli Lilly and Company $16,430 27 payments
  9. Nestle HealthCare Nutrition Inc. $14,349 22 payments
  10. Gilead Sciences, Inc. $7,454 13 payments
  11. Other $15,704 356 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,635,688 552 payments
  2. Travel and Lodging $210,496 615 payments
  3. Consulting Fee $105,166 36 payments
  4. Food and Beverage $55,373 1,288 payments
  5. Honoraria $29,748 10 payments
  6. Education $130 9 payments
Products named General payments · program years 2019–2025
  1. STELARA $465,099 469 payments
  2. RINVOQ $263,469 339 payments
  3. TREMFYA $255,815 294 payments
  4. ZEPOSIA $249,394 219 payments
  5. OMVOH $189,898 175 payments
  6. HUMIRA $174,223 185 payments
  7. SKYRIZI Immunology $160,098 221 payments
  8. SKYRIZI Immunology $114,013 109 payments
  9. VELSIPITY $82,069 89 payments
  10. ZYMFENTRA $44,862 45 payments
  11. Other $22,866 461 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $1,925 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,376

Median for Gastroenterology: 569

Drug cost

$1,249,137

Median for Gastroenterology: $104,976

Branded share of claims

33.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 36 $880,940
Rinvoq Upadacitinib Brand 12 $84,734
Linzess Linaclotide Brand 65 $72,128
Creon Lipase/Protease/Amylase Brand 28 $59,616
Rezdiffra Resmetirom Brand 14 $55,463
Zenpep Lipase/Protease/Amylase Brand 11 $21,911
Mounjaro Tirzepatide Brand 13 $14,029
Budesonide Er Budesonide Brand 14 $12,532
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 120 $7,110
Movantik Naloxegol Oxalate Brand 14 $6,119

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$113,891

Medicare's payments for the services billed

Medicare patients

318

Average age 75

Services billed

946

178 women, 140 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 51%
Ischemic heart disease 30%
Diabetes 21%
Atrial fibrillation 21%
Chronic kidney disease 20%
Osteoporosis 20%
Depression 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OMVOH
$100,043 — —
SKYRIZI
$84,568 — —
TREMFYA
$71,810 — —
STELARA
$64,967 36 —
RINVOQ
$57,002 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

2,511 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record